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Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated
with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with
bevacizumab (bev) plus chemotherapy in the first-line setting.
Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or
irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary
endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab
and risk factors including location of metastases were evaluated.
Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS
(wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312).
Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001).
We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease.
Conclusion: KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus
chemotherapy in mCRC patients.
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practiceBackground
Access to the host vascular system and the formation of
tumor blood supply represent a limitation for the pro-
gression of solid tumors. A switch to an angiogenic
phenotype occurs early in tumorigenesis and is induced
by hypoxia, metabolic stress, or oncogene activation.
The vascular endothelial growth factor (VEGF) family of
ligands and their receptors play a crucial role in tumor
angiogenesis and neovascularization. VEGF stimulates
proliferation of endothelial cells, vascular permeability,
and attracts bone marrow-derived endothelial precursors
to the tumor microenvironment. Increased levels of pro-* Correspondence: dubska@mou.cz
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unless otherwise stated.angiogenic factors and tumor vascularization are associ-
ated with increased risk of tumor metastases and inferior
survival of patients with metastatic colon cancer and
other types of cancer [1].
Bevacizumab (bev) is a recombinant, humanized,
monoclonal antibody that inhibits VEGF receptor signal-
ing by binding to VEGF-A. Bevacizumab was the first
angiogenic inhibitor shown to prolong survival in ad-
vanced cancer [2]. Bev in combination with chemother-
apy significantly improves progression-free survival and
overall survival in the first- and second-line treatment of
metastatic colorectal cancer (mCRC) [3,4].
Currently, tumor KRAS gene status remains one of
the most important predictive biomarker used in man-
agement of colorectal carcinoma. Beside its established
role in anti-EGFR therapy, KRAS mutation may also
affect the clinical outcome of anti-angiogenic therapy.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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duce angiogenesis via several mechanisms. Oncogenic
mutations of Ras intracellular signal transducers can in-
crease VEGF production by tumor cells [1,5]. Moreover,
activating Ras mutation resulted in up-regulation of pro-
angiogenic interleukin-8 (CXCL-8) leading to recruit-
ment of endothelial cells, tumor vascularisation and
tumor growth in vitro [6] and more aggressive biological
behavior in vivo [7]. Additionally, Ras signaling pro-
moted angiogenesis through repression of anti-angiogenic
thrombospondin-1 [8]. Thus, Ras oncogenes may contrib-
ute to tumor progression by both a direct effect on tumor
cell proliferation as well as indirectly by facilitating tumor
angiogenesis in a paracrine fashion.
The aim of the present observational study was to as-
sess the role of KRAS status in mCRC patient treated in
the the first-line with anti-angiogenic agent bevacizumab
combined with oxaliplatin- or irinotecan-based chemo-
therapy in current clinical practice. Furthermore, we
aimed to identify risk factors related to disease charac-




Data from 1622 mCRC patients with known KRAS sta-
tus who received first-line bevacizumab plus FOLFOX,
XELOX, FOLFIRI or XELIRI between January 2005 and
April 2013 were mined from the non-interventional
post-registration database collecting epidemiological and
clinical data of patients with advanced and metastatic
CRC on targeted treatment (CORECT registry). The
protocol was approved by the independent ethics com-
mittee at each participating centre (Ethics Committee
(EC) of the Ceske Budejovice Hospital, EC of the
Chomutov Hospital, EC of the General University Hos-
pital in Prague, EC of the Jihlava Hospital, EC of the
Liberec Regional Hospital, EC of the Masaryk Hospital
in Usti nad Labem, EC of the Masaryk Memorial Cancer
Institute in Brno, EC of the Na Bulovce Hospital in
Prague, EC of the Na Homolce Hospital in Prague, EC
of the Novy Jicin Hospital, EC of the Pardubice Regional
Hospital, EC of the St. Anne’s University Hospital (UH)
in Brno, EC of the Thomayer Hospital in Prague, EC of
the Tomas Bata Regional Hospital in Zlin, EC of the UH
Brno, EC of the UH Hradec Kralove, EC of the UH in
Motol, Prague, EC of the UH Olomouc, EC of the UH
Ostrava, EC of the UH Pilsen) and complied with the
International Ethical Guidelines for Biomedical Research
Involving Human Subjects, Good Clinical Practice guide-
lines, the Declaration of Helsinki, and local laws. The
CORECT database includes data of approximately 96% of
all mCRC patients treated with targeted therapies in the
Czech Republic. The security of individual records isguaranteed via de-identified data collection and the system
meets all valid rules on the protection of personal data.
Only authorized users can access the system. No exclusion
criteria were applied in data input, mining or analysis.
Evaluated parameters
KRAS testing
Tumor tissue samples were tested in local referral la-
boratories to identify mutations in codons 12 and 13 of
exon 2 of the KRAS gene using established methods ac-
cording to American Society of Clinical Oncology guide-
lines. In the Czech Republic in 2009, 60.2% colorectal
tumors were tested as wild-type KRAS (wtKRAS) and the
incidence of mutation detected was as follows: G12D
(11.9%), G12V (8.8%), G13D (5.8%), G12C (3.3%), G12A
(2.8%), G12S (2.0%), G12R (1.0%), G13C (0.3%), G13V
(0.1%) [9].
Treatment
Choice of chemotherapy backbone regimen was at the
physicians’ discretion according to national guidelines
based on European Society for Medical Oncology guide-
lines. The dosage of chemotherapeutic agents were de-
termined according to the body surface area and dose
reduction was recommended only in cases of severe
(grade 3) adverse events to assure optimal chemotherapy
dose intensity. The chemotherapy regimens were as fol-
lows: FOLFOX4 (oxaliplatin 85 mg/m2 IV day1; leucov-
orin 200 mg/m2 IV days 1 and 2; 5-FU bolus 400 mg/m2
IV days 1 and 2; 5-FU 600 mg/m2 IV 22-hour continu-
ous infusion days 1 and 2 every 2 weeks), FOLFIRI (iri-
notecan 180 mg/m2 IV day 1; leucovorin 200 mg/m2 IV
day 1 and 2; 5-FU 600 mg/m2 IV 22-hour continuous in-
fusion days 1 and 2 every 2 weeks), XELOX (oxaliplatin
130 mg/m2 IV day 1; capecitabine 1000 mg/m2 twice
daily PO for 14 days every 3 weeks), or XELIRI (irinote-
can 250 mg/m2 IV day 1; capecitabine 1000 mg/m2 twice
daily PO for 14 days every 3 weeks). Bevacizumab was
administered at a dosage of 5 mg/kg IV every 2 weeks or
7.5 mg/kg IV every 3 weeks depending on the chemother-
apy regimen. Dosage of bevacizumab was not reduced.
Clinical response and follow-up
Data were reported to the registry every 6 months. Pa-
tients’ response to treatment and tumor measurements
were determined by independent evaluation by two local
radiologists according RECIST version 1.0. Patients were
followed-up until death or loss to follow-up.
Statistical analyses
Standard descriptive statistics were used to characterize
the sample data set. Differences in initial categorical pa-
rameters were assessed using the Pearson chi-square test.
Comparisons of the subgroups in continuous variables
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vival (OS) and progression-free survival (PFS) were esti-
mated using the Kaplan-Meier method. OS was defined as
the time from bevacizumab treatment initiation to death
due to any cause. PFS was defined as the time from bev
treatment initiation to progression or death due to any
cause. Statistical significance of the differences in Kaplan-
Meier estimates was assessed using the log-rank test. For
all point estimates the 95% confidence interval (95% CI)
was calculated. The univariate Cox proportional hazards
model was used to evaluate the influence of all potential
predictive and prognostic factors on the survival measures
and subsequently the multivariable Cox proportional haz-
ards model was used to quantify the influence of KRAS
status on survival in the presence of other potential
predictive and prognostic factors. A level of significance
α = 0.05 was used in decision on statistical significance.Results
KRAS status and disease characteristics
KRAS mutations were reported in 40.6% of mCRC pa-
tients studied; the remaining 59.4% of patients had wild-
type KRAS tumors. The occurrence of KRAS somatic
mutation was distributed evenly between men and
women. The median age of patients with KRAS muta-
tions was two years older than that of patients without
mutation (p < 0.001). The distribution of KRAS status
did not differ between primary tumors located in colon
or rectum. However, we observed that patients present-
ing with synchronous metastases were more likely to
have a tumor with KRAS mutation (p = 0.049). Resect-
ability of metastases in mutant KRAS subgroup was
comparable to resectability in wtKRAS patients. KRAS
mutation was not associated with multiple metastatic
sites at the time of therapy initiation. Nevertheless, we
observed that KRAS mutated tumors metastasized more
often to lungs (p = 0.001) (Table 1).Treatment characteristics and clinical outcome of
bevacizumab plus chemotherapy
There was no evident bias caused by the uneven distri-
bution of cases with KRAS mutation in two bevacizu-
mab schedules, chemotherapeutic regimens, or first-line
treatment duration. Patients with mutated KRAS tumors
achieved the best treatment response and a response
rate equal to the clinical outcome of the wtKRAS sub-
group (Table 1). Median PFS from treatment initiation
was 11.5 months (95% CI 11.0 - 12.1). Median overall
survival was 29.5 months (95% CI 27.8 - 31.2). The beva-
cizumab regimen every 2 versus every 3 weeks resulted
in comparable PFS and OS (data not shown). Median
PFS was 11.5 months in wtKRAS patients vs 11.4 months
in mtKRAS subgroup (Figure 1A) and median OS was inwtKRAS patients 30.7 months over 28.4 months in pa-
tients with KRAS mutation (Figure 1B).Toxicity related to first-line treatment with bevacizumab
The most frequent adverse events considered to be re-
lated to bevacizumab were thromboembolic complica-
tion in 58 (3.6%) patients, hypertension in 53 (3.3%),
proteinuria in 26 (1.6%), bleeding in 20 (1.2%), and GIT
perforation in 6 (0.3%) patients. The grade 3 or 4 ad-
verse events related to bevacizumab had the following
occurrence: thromboembolic disease in 20 (1.2%) pa-
tients, hypertension in 18 (1.1%), bleeding in 5 (0.3%),
GIT perforation in 2 (0.1%), and proteinuria in 1 (0.1%).
KRAS status had no influence on the incidence of ad-
verse events, their severity (data not shown) or termin-
ation of therapy for toxicity (Table 1).Factors affecting clinical outcome of treatment for mCRC
Multivariable Cox analyses (Figure 2) confirmed risk fac-
tors affecting the outcome from first-line treatment with
bev plus chemotherapy observed in univariate Cox ana-
lysis (data not shown). Beside KRAS status, progression
free survival was independent of gender, age, site of pri-
mary tumor, presence of synchronous metastasis, and
chemotherapy regimen (Figure 2). Presence of multiple
metastatic sites at the time of therapy initiation was the
risk factor for early progression (HR = 1.51; p < 0.001)
and this risk was higher in patients with KRAS mutation
(HR = 1.77; 95% CI 1.43 - 2.18) compared to patients
with wtKRAS (HR = 1.37; 95% CI 1.16 - 1.62). Overall
survival tended to be improved in patients treated in the
first line with bevacizumab with oxaliplatin compared to
irinotecan-based chemotherapy (HR = 0.81, p = 0.052).
Patients presenting with synchronous metastases had
shorter overall survival (HR = 1.24; p = 0.015) and in the
subgroup analysis, the significance of this effect was lim-
ited to wtKRAS subgroup (HR = 1.25; p = 0.020). Simi-
larly to PFS, presence of multiple metastatic sites was
the risk factor for shorter overall survival (HR = 1.59;
p < 0.001).
KRAS subgroup analysis of clinical outcome in the
context of chemotherapy backbone confirmed similar
PFS in patients treated with bev/OX-based or bev/IRI-
based with or without KRAS mutation (p = 0.716;
Figure 3A). In patients with wtKRAS tumors, median
OS was 31.0 months in bev/OX-based subgroup and
29.2 months in case of bev/IRI-based first-line treat-
ment. In patients with KRAS mutation, median OS was
29.1 months in bev/OX-based treatment and 24.2 months
in bev/IRI-based subgroup (p = 0.192, Figure 3B). Thus,
the trend toward relatively improved overall survival in
patients who started with bev plus XELOX or FOLFOX
may be explained by shorter OS in KRAS mutant patients
Table 1 Patients, disease and treatment characteristics
WT KRAS (n = 964) KRAS mutation (n = 658) p-value
Male, n (%) 593 (61.5) 405 (61.6) 0.999
Age at bevacizumab treatment initiation, median, (min-max) 61 yrs (22–85) 63 yrs (22–83) <0.001
Site of primary tumor, n (%)
Colon 593 (61.5) 398 (60.5) 0.679
Rectum 371 (38.5) 260 (39.5)
PS at 1st line treatment initiation*, n (%)
PS 0 378 (52.2) 264 (51.5) 0.811
PS 1 333 (46.0) 242 (47.2)
PS 2 or PS 3 13 (1.8) 7 (1.4)
Adjuvant chemotherapy**, n (%) 317 (32.9) 189 (28.7) 0.081
Resectability of metastases*
Unresectable 543 (76.5) 374 (75.7) 0.695
Potentially resectable 127 (17.9) 96 (19.4)
Resectable 40 (5.6) 24 (4.9)
Sites of metastases at the time of the initiation of fist-line treatment*, n (%)
Liver 518 (67.7) 350 (64.0) 0.174
Lymph nodes 235 (30.7) 143 (26.1) 0.073
Lungs 182 (23.8) 175 (32.0) 0.001
Peritoneum 137 (17.9) 111 (20.3) 0.284
Other localization 116 (15.2) 78 (14.3) 0.693
2 and more metastasis 338 (44.2) 238 (43.5) 0.822
Bevacizumab regimen in first-line treatment, n (%)
5 mg/kg every 2 weeks 613 (63.6) 436 (66.3) 0.290
7.5 mg/kg every 3 weeks 351 (36.4) 222 (33.7)
CT at first-line treatment initiation, n (%)
FOLFOX 511 (53.0) 366 (55.6) 0.259
XELOX 295 (30.6) 184 (28.0)
FOLFIRI 107 (11.1) 83 (12.6)
XELIRI 51 (5.3) 25 (3.8)
Reason for first-line therapy termination, n (%)
Disease progression 534 (64.7) 342 (63.0) 0.162
Surgery 52 (6.3) 47 (8.7)
Adverse event of bevacizumab 48 (5.8) 24 (4.4)
Adverse event of chemotherapy 18 (2.2) 17 (3.1)
Other reason*** 173 (17.9) 113 (20.8)
Subsequent anti-EGFR-based treatment, n (%)****
In second line 342 (35.5) 15 (2.3) -
In third line 245 (25.4) 8 (1.2)
In fourth line 21 (2.2) 3 (0.5)
M, presence of distant metastasis; PS, performance status; *PS data were available for 75% of patients in the wtKRAS subgroup and for 78% patients in the mutant KRAS
subgroup. Data on metastasis sites at first-line treatment initiation was available in 79% and 83% of patients, respectively. Data on metastases resectability were available
for 74% and 75% patients, respectively. **Adjuvant regimens included FUFA biweekly infusional 5-FU/LV, FOLFOX, capecitabine, and not specified adjuvant CT. ***Other
reason for first-line therapy termination included lack of data availability, CR, patient refusal, and death. ****The regimen with anti-EGFR antibodies were following:
FOLFOX4+ panitumumab, FOLFIRI + panitumumab, FOLFOX4 + cetuximab, FOLFIRI + cetuximab, irinotecan (250 mg/m2 IV every 2 weeks) + cetuximab, panitumumab or
cetuximab as single agents. Schedules and dosage of chemotherapy was identical to those applied in the first-line treatment. Panitumumab was administered 6 mg/kg
IV every 2 weeks, cetuximab was administered 500 mg/m2 IV every 2 weeks or 400 mg/m2 IV first infusion, then 250 mg/m2 IV weekly. The registry did not provide
reliable data on number of patients treated subsequently with chemotherapy alone. The chemotherapeutic regimen applied without addition of anti-EGFR antibodies
were FOLFOX, FOLFIRI, XELOX or XELIRI as defined in Methods section.
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KRAS mutation - 28.4 months (25.6; 31.2)
WT KRAS - 30.7 months (28.3; 33.0)
Median OS
Figure 1 Progression-free survival and overall survival according to KRAS mutation. A - progression-free survival; B – overall survival.
Progression free survival characteristics in wtKRAS vs mtKRAS subgroups were as follows: 1-year PFS 47.3 (95% CI 43.9 - 50.7) vs 47.7% (95% CI
43.5 - 51.9), 2-year PFS 15.9 (95% CI 13.2 - 18.5) vs 17.5% (95% CI 14.0 - 21.0), 3-year PFS 8.0 (95% CI 5.8 - 10.2) vs 8.9 (95% CI 6.1 - 11.8). Overall
survival characteristics in wtKRAS vs mtKRAS subgroups were as follows: 1-year OS 88.1 (95% CI 85.9 - 90.3) vs 89.2% (95% CI 86.6 - 91.8), 2-year
PFS 63.0 (95% CI 59.5 - 66.5) vs 58.5% (95% CI 53.8 - 63.2), 3-year PFS 41.8 (95% CI 37.8 - 45.8) vs 38.1 (95% CI 32.8 - 43.5).
Figure 2 Results of multivariable Cox analysis for progression-free survival and overall survival. OX-based, FOLFOX or XELOX; IRI-based,
FOLFIRI or XELIRI.
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Figure 3 Progression-free survival and overall survival according to KRAS mutation and type of chemotherapy. A - progression-free
survival; B – overall survival.
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backbone.
KRAS subgroup analysis of clinical outcome in the
context of location of metastatic disease revealed no
difference in PFS between patients with only hepatic
wtKRAS metastatic involvement (median PFS 12.9
months; 95% CI 11.6 - 14.2) compared to mtKRAS/hep-
atic subgroup (median PFS 12.1 months; 95% CI 10.2 -
14.0; p = 0.956). Similarly, median OS was 33.9 months
(95% CI 30.2 - 37.7) in wtKRAS/hepatic subgroup and
29.2 months (95% CI 26.4 - 32.0) in mtKRAS/hepatic
subgroup (p = 0.542). Similarly, the difference in PFS or
OS between wtRAS and mtKRAS was not observed for
metastatic involvement of lungs, peritoneum or lymph
nodes (Figure 4). Location of metastasis in single organ
involvement was also not associated with effect on PFS
or OS (Figure 4).
Discussion
The present data demonstrates that mCRC patients
treated with bevacizumab plus combination chemother-
apy have similar outcomes regardless of KRAS mutation
status. Currently, standard first-line treatment for pa-
tients with mCRC includes combination chemotherapy
with either an anti-EGFR agent (cetuximab or panitumu-
mab), or bevacizumab. Adding bevacizumab to chemo-
therapy prolongs survival in advanced colorectal cancer
patients. However, not all mCRC patients respond to
this treatment and identification of a subgroup of pa-
tients who will benefit most from bevacizumab currently
represents a challenge. Data on the prognostic and/or
predictive significance of KRAS status in mCRC patients
treated with first-line bevacizumab-containing regimens
were obtained mostly as secondary endpoints in trialscomparing bevacizumab vs anti-EGFR therapy efficacy
(see Additional file 1: Table S1). In general, these studies
failed to demonstrate KRAS status as a predictive factor
for anti-VEGF therapy in the first-line treatment of
mCRC, consistent with the present study. The results of
the MACRO trial indicated that KRAS status may be a
prognostic factor in mCRC patients treated with bevacizu-
mab; however, that study setting did not allow the evalu-
ation of the predictive role of KRAS status [10]. Evaluation
of OS in the studies evaluating the prognostic role of
KRAS in patients treated with first-line bevacizumab,
including the present study (summarized in Additional
file 1: Table S1), is difficult because the patients’ survival
is influenced by subsequent line of therapy and patients
with wtKRAS tumors could benefit often from anti-
EGFR therapy after progression on bev/chemotherapy.
Accordingly, the insignificant prolongation of overall sur-
vival by 2.3 months in wtKRAS patients over the mutated
KRAS subgroup may be to some extent attributed to sub-
sequent anti-EGFR therapy (Table 1).
The adverse events from bevacizumab treatment ob-
served in this study are consistent with those published
in post-registrational trials, including BEAT, BRiTE and
ARIES [11-13]. We confirmed that severe (grade 3–5)
events, including arterial thromboembolic events, pro-
teinuria, gastrointestinal perforation and wound-healing
complications were rare with incidence and spectrum of
adverse events comparable across all age groups [14].
Taken together, the adverse events related to bevacizu-
mab are acceptable and well tolerated.
Prospective data on the optimal sequence of chemo-
therapy regimen used with targeted therapy of metastatic
colorectal cancer is lacking. It has been demonstrated
that first-line regimens combining fluoropyrimidines
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OS=29.2 months (26.4; 32.0)
Lungs (n=52)
OS=42.2 months (38.5; 45.9)
p=0.081 
Lymph nodes (n=19)





PFS=12.9 months (11.6; 14.2) 
Lungs (n=47)
PFS=12.6 months (9.7; 15.6) 
p=0.254 
Lymph nodes (n=26)
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WT KRAS
Liver (n=173)
PFS=12.1 months (10.2; 14.0)
Lungs (n=52)
PFS=14.7 months (10.7; 18.8)
p=0.127 
Lymph nodes (n=19)
PFS=20.0 months (12.4; 27.7)
Peritoneum (n=29)
PFS=16.9 months (14.0; 19.8)
KRAS mutation
Figure 4 Progression-free survival and overall survival according to KRAS mutation and metastatic site in patients with metastatic
disease limited to one distant organ. A, C – progression-free survival; B, D – overall survival.
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[15,16]. Accordingly, the optimal choice for the chemo-
therapy to be used in combination with bevacizumab in
the initial treatment of mCRC should be based on the
characteristics of the patient and tumor, as well as the
drug efficacy and toxicity profile. FOLFOX or XELOX is
considered as a convenient first-line treatment option
for mCRC patients as they cause less diarrhea, nausea,
and alopecia than FOLFIRI or XELIRI, despite a poten-
tial for dose-limiting neurotoxicity. In the present study,
patients who received in the first line bev/OX-based
chemotherapy tended to have longer overall survival
over those treated with irinotecan-based chemotherapy
with bevacizumab. As we did not observe a difference in
performance status (ECOG of 0 or 1) between patients
who started treatment with bev/OX versus bev/IRI-
based therapy in the first-line setting (data not shown),
the trend toward better OS in bev/OX subgroup is un-
likely to be attributed to better performance status in
these patients. Interestingly, the inferior efficacy of treat-
ment with the irinotecan backbone was restricted to the
subgroup of patients with KRAS mutation, with median
OS in the bev/OX-based subgroup being 5 months lon-
ger than in the bev/IRI-based treatment. Based on
in vitro experiments showing that KRAS mutation is apredictor of oxaliplatin sensitivity in colon cancer cells,
it has been suggested that mutant KRAS CRC patients
might benefit more from receiving first-line oxaliplatin-
based regimens [17]. Although we have not observed a
better response in KRAS mutated mCRC patients treated
with bev/OX-based therapy over those with wtKRAS, as it
was reported when patients with advanced CRC were
treated in the first line with FOLFOX-6 [18], the reported
sensitivity of mutated KRAS carcinoma cells to oxaliplatin
may explain the improved clinical outcome when KRAS
mutant patients were treated with bev/OX-based over
bev/IRI-based therapy.
We have confirmed that patients presenting with syn-
chronous metastases have an inferior prognosis com-
pared to patients with metachronous metastases. Among
the evaluated parameters, metastatic involvement of
multiple organs at time of treatment initiation was the
strongest prognostic factor reducing both PFS and OS.
Within the subgroup of patients with metastatic disease
limited to one distant organ we did not observed differ-
ence in clinical outcome with regard to hepatic or extrahe-
patic (including pulmonary) involvement. Interestingly,
together with Rossi et al. [19], we observe trend toward
longer both PFS and OS in patients with extrahepatic dis-
ease and KRAS mutation than in wtKRAS subgroup when
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this fact, we and others [20-22] have reported that KRAS
mutation in colorectal cancer itself is associated with pul-
monary metastasis. Findings from the VICTOR trial show-
ing that KRAS mutant tumors are associated with an
increased risk of lung relapse in CRC patients supported
the role of chest imaging in surveillance of colorectal
cancer patients, particularly of those with resected pri-
mary mutated KRAS carcinoma [20,22]. The reason for
increased incidence of lung metastases in KRAS mutated
colorectal tumors remains unknown at this moment.
Considering the decreased proportion of lymph node me-
tastasis in mutated KRAS patients compared to wtKRAS
subgroup (Table 1, [23,24]), it seems that carcinoma cells
with activating mutation in KRAS may exhibit a more
hematogenous metastatic spread rather than along a lym-
phogenous path. Survival of tumor cells within the blood-
stream and adhesion in the vasculature at the metastatic
sites depend on tumor cell – platelet interactions [25]. We
hypothesize that activating mutation of KRAS inducing
expression of molecules responsible for interaction with
platelets, such as tissue factor [26], cyclooxygenase and
metalloproteinase-9 [27], or cathepsin B [28] might con-
tribute to increased protection of these carcinoma cells
against shear stress as well as to enhanced adhesion
properties which in turn leads to onset of pulmonary me-
tastasis of mutated KRAS carcinoma cells and higher
metastatic activity in general [29].
The present study is a retrospective analysis, and thus
an unintentional selection bias for a subset of patients is
possible. However, the parameters of our analysis that
confer substantial reliability to the presented results are,
for example, unselective multicenter input of evaluated
data and the proportion of tumors with wtKRAS vs
mtKRAS, mirroring the proportion of KRAS mutation
previously detected in the Czech Republic during a one
year survey [9]. We excluded a potential bias caused by
inclusion patients with known KRAS status only, as no
difference was observed between PFS of mCRC patients
treated in the first-line with bevacizumab and OX- or
IRI-based chemotherapy with KRAS-known (11.5 months,
95% CI 11.0-12.1) and KRAS-unknown (11.6 months,
95% CI 11.0-12.2) which is further underlined by KRAS-
unselected published data on first-line bevacizumab in
mCRC patients based on CORECT registry [14]. An exist-
ing limitation of the present study is that we had no data
specifying the type of KRAS mutation, NRAS mutation or
data on BRAF mutation. Mutation of BRAF and KRAS
are, in the vast majority cases, mutually exclusive, and
thus, the wtKRAS subgroup in the present study included
an unknown number of BRAF mutated cases who might
have worse survival rates. However, estimating from our
findings of BRAF mutations in 3.8% of mCRC patients
(unpublished data from diagnostic testing), contaminationof the wtKRAS subgroup with mutant BRAF patients is
unlikely to have been substantial. Regarding specific muta-
tions in the KRAS gene, there is emerging data showing
that mutation in codon 13 leads to a more aggressive dis-
ease course with extensive synchronous metastases com-
pared to colorectal carcinoma with mutation in codon 12
[30]. Mutation in codon 13 is reported to confer worse
prognosis and outcome than alteration in codon 12 [31].
On the other hand, when treated with cetuximab and
chemotherapy, patients with mutation in codon 13 dem-
onstrated a trend toward longer PFS than the codon 12-
mutated subgroup but also a better outcome than patients
with tumors without KRAS mutation [30,31]. KRAS
codon 12 (Cys12 = G12C) or codon 13 (Asp13 = G13D)
mutation resulted in different vascular strategy in vitro;
the neovascularization in Asp13 cells was associated with
high levels of VEGF-A but less effective vasculature com-
pared to their Cys12 counterpart [32]. Moreover, a trend
toward increased vascular invasion in codon 13-mutated
tumors has been observed in colorectal cancer patients
[33]. Thus, the different biological role of KRAS mutation
in codon 13 may have also implications for anti-angiogenic
treatment with bevacizumab.
Conclusion
The present study demonstrates that KRAS mutation in
codon 12 or 13 does not interfere with clinical benefit
from bevacizumab plus chemotherapy in patients with
mCRC during first- line therapy. We speculate that this
finding reflects specific aspects of mutated KRAS tumor
biology rather than an irrelevance of KRAS in bev/
chemotherapy outcome. One factor might be the relative
sensitivity of KRAS-mutated carcinoma cells to oxalipla-
tin. Another factor might be enhanced pro-angiogenic
properties of CRC cells with KRAS mutation which,
however, might be restricted to certain KRAS mutation
subtypes [32,34]. These cancers might be somewhat
more “angiogenesis-dependent” and therefore more sen-
sitive to VEGF withdrawal caused by bevacizumab. Simi-
larly, a high expression of VEGF-A and VEGFR-2
predicted improved PFS in metastatic breast cancer pa-
tients treated with docetaxel/bevacizumab [35]. Taken
together, it is becoming clear that establishment of a
predictive role of KRAS mutation for treatment of
mCRC with chemotherapy and biological agents, includ-
ing bevacizumab, cannot be elucidated without evalu-
ation of specific KRAS mutations.Additional file
Additional file 1: Table S1. Results of first-line bevacizumab and
chemotherapy treatment in phase III trials or large-scale studies of
metastatic colorectal cancer patients with wt versus mutated KRAS.
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